Polyrizon Unveils NASARIX™ As The Official Brand Name For Its PL-14 Allergy Blocker Following Completed Global Branding Process

Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced that it has completed the branding process for its PL-14 allergy blocker. The product will be introduced under the brand name NASARIX™, marking a significant step as the company prepares for future commercialization.

NASARIX™ is built on Polyrizon’s proprietary Capture and Contain™ hydrogel technology, an innovative intranasal spray formulation designed to create a physical protective barrier inside the nasal cavity. This barrier helps reduce exposure to allergens and viruses, offering a differentiated approach to respiratory protection. Establishing the NASARIX™ brand strengthens Polyrizon’s ability to communicate the product’s benefits clearly to patients, healthcare providers, and potential commercial collaborators.

As part of the branding initiative, the company conducted extensive trademark and linguistic assessments across both U.S. and European markets. These evaluations ensure that the brand name meets regulatory expectations, resonates well across key geographies, and supports long-term commercial positioning.

Tomer Izraeli, Chief Executive Officer of Polyrizon, noted that choosing the NASARIX™ brand reflects the company’s readiness to move closer to clinical and regulatory milestones. He emphasized that the name helps build a strong and recognizable identity in the allergy and respiratory health space, supporting Polyrizon’s broader strategic goals. The company expects NASARIX™ to be introduced in alignment with its clinical progress and regulatory development timeline as it advances PL-14 toward future market opportunities.